Literature DB >> 9691218

Mice transgenic for simian immunodeficiency virus nef are immunologically compromised.

N B Larsen1, H W Kestler, J J Docherty.   

Abstract

An intact nef gene is essential for rapid development of immunodeficiency in human immunodeficiency virus and simian immunodeficiency virus infections. To assess the role of nef in the immune response, mice transgenic for SIV nef were constructed and the humoral and cellular immune response to herpes simplex virus type-1 (HSV-1), measured. Mice transgenic for SIVmac239 nef exhibited a significantly increased mortality rate when challenged with HSV-1 and also showed unusual antibody kinetics in response to viral challenge. During a 32-week period following exposure to HSV, it was noted that IgG subclass titers continued to rise in the nef+ animals, while titers of nef- animals decreased. Additionally, following secondary challenge with HSV, nef- mice had a significantly greater rise in HSV-neutralizing antibody titers than nef+ mice. A decreased proliferative response to the T cell mitogen, PHA, was noted in the nef+ animals. These results suggest that the presence of nef+ is sufficient to induce immune dysfunction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9691218     DOI: 10.1007/bf02255857

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  2 in total

1.  Expression of simian immunodeficiency virus nef in immune cells of transgenic mice leads to a severe AIDS-like disease.

Authors:  Marie-Chantal Simard; Pavel Chrobak; Denis G Kay; Zaher Hanna; Serge Jothy; Paul Jolicoeur
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Primary human immunodeficiency virus type 1 nef alleles show major differences in pathogenicity in transgenic mice.

Authors:  Elena Priceputu; Zaher Hanna; Chunyan Hu; Marie-Chantal Simard; Patrick Vincent; Steffen Wildum; Michael Schindler; Frank Kirchhoff; Paul Jolicoeur
Journal:  J Virol       Date:  2007-02-21       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.